Christopher D. Comeau focuses his practice on representing public companies and financial investors in connection with public and private merger and acquisition and minority investment transactions. The public companies Chris represents operate primarily in the life sciences industry.
The financial investors Chris represents invest primarily in middle market companies in a wide range of industries, including consumer products and retail brands, services, and manufacturing. Chris has led recent transactions for Cubist, Shire, Pfizer, TSG Consumer Partners, Gridiron Capital, Samsonite, Johnson & Johnson, GT Advanced Technologies and Genzyme Corporation.
Prior to joining Ropes & Gray, Chris spent three years with Coopers & Lybrand LLP, a predecessor firm to PricewaterhouseCoopers LLP.
EDUCATION :
- JD, magna cum laude, Georgetown University Law Center, 1999; Fegan Award; Editor, Georgetown Law Journal
- BA, Amherst College, 1993
ADMISSIONS : Massachusetts, 1999
Experience :
- Represented Pfizer in connection with its $14 billion acquisition of Medivation, a commercial-stage oncology company.
- Represented Shire in connection with its $36 billion combination with Baxalta, a business spun out of Baxter International, for a combination of cash and stock.
- Represented Mattress Firm, the largest US speciality mattress retailer, in connection with its $4 billion sale to Steinhoff International.
- Represented Medtronic in connection with its $1.3 billion acquisition of HeartWare International, a heart pump manufacturer.
- Represented Performance Health in connection with its initial public offering registration and ultimate sale to Patterson Medical for an undisclosed amount.
- Represented Cubist Pharmaceuticals in connection with its simultaneously announced $801 million acquisition of Optimer and $818 million acquisition of Trius Therapeutics.
- Represented Inspiration Biopharmaceuticals in connection with the sale of its Factor IX and OBI-1 products to Cangene Corporation and Baxter out of bankruptcy in exchange for payments that could exceed $1 billion.
- Represented Genzyme Corporation in connection with its divestiture of three non-core business units, including the sale of its Genzyme Genetics business unit to Laboratory Corporation of America for $925 million.
- Represented a special committee of the board of directors of Affiliated Computer Services, Inc., in connection with the $8.3 billion sale of ACS to Xerox Corporation.
- Represented KarpReilly in connection with its investments in The Habit Burger Grill, Trina Turk, and Hooters of America/Texas Wings.
- Represented Berkshire Partners in connection its sale of Fresh Start Bakeries and Party City’s acquisition of a franchisee.
Cost
Rate : $$$